Immuneering Corp
IMRXDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
15dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How IMRX's past catalysts played out
Atebimetinib
Pancreatic Cancer
IMM-1-104 Monotherapy (Treatment Group A)
Advanced Solid Tumor
IMM-6-415
Advanced Solid Tumor (Phase 1)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Atebimetinib | Phase 3 | Pancreatic Cancer | - | - |
IMM-1-104 Monotherapy (Treatment Group A) | Phase 2 | Advanced Solid Tumor | - | - |
IMM-6-415 | Phase 2 | Advanced Solid Tumor (Phase 1) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Immuneering Corp's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Immuneering Corp's (IMRX) pipeline across Phase 3, Phase 2. Its lead program is Atebimetinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immuneering Corp's next FDA catalyst?→
Immuneering Corp's (IMRX) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMRX biotech catalysts?→
Add IMRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immuneering Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.